Effect of warm-supplementing kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: A randomized controlled trial

Clinical Rehabilitation

Volumn 23, Issue 11, 2009, Pages 963-972

  Chen, Zhen Hua ^a   Wang, Gao Hua ^a   Wang, Xiao Ping ^a   Huo, Yun Xiang ^b   Yang, Ming Hua ^c   Li, Li ^a   Mei, Hong Bing ^b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Youfu Hospital of Wuhan   (China)

^c Third Renmin Hospital of Jingmen of Hubei province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHINESE DRUG; PLACEBO; RISPERIDONE; UNCLASSIFIED DRUG; WARM SUPPLEMENTING KIDNEY YANG;

AKATHISIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; HAMILTON SCALE; HUMAN; INSOMNIA; LASSITUDE; MAJOR CLINICAL STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; QUALITY OF LIFE; QUALITY OF LIFE SCALE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL DISABILITY SCREENING SCHEDULE SCALE; SOCIAL STATUS; SOMNOLENCE; TREMOR; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 71049159548     PISSN: 02692155     EISSN: 14770873     Source Type: Journal    
DOI: 10.1177/0269215508101743     Document Type: Article

References (40)

1. Murphy BP, Chung YC, Park TW, McGorry PD Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophr Res 2006; 88: 5-25.
2. Kane JM Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999; 46: 1396-408.
3. Olie JP, Ghaoui S., Bayle FJ New antipsychotic agents. Encephale 1999; 259: 52-60.
4. King DJ Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 1998; 8: 33-42.
5. Beasley Jr CM, Tollefson G., Tran P., Satterlee W., Sange T., Hamilton S. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111-23.
6. Lieberman JA, Safferman AZ, Pollack S. et al. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. Am J Psychiatry 1994; 151: 1744-52.
7. Sepehry AA, Potvin S., Elie R., Stip E. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: A meta-analysis. J Clin Psychiatry 2007; 68: 604-10.
8. Tsai G., Lane HY, Yang P., Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 452-56.
9. Cheng HQ Traditional Chinese Medicine. Wuhan, Huazhong Education University Publisher, 1988.
10. National Pharmacopoeia Commission. Pharmacopoeia of People's Republic Nation of China. Beijing, Beijing Chemistry Industry Publishing Company, 2000.
11. Cai DF, Shen ZY, Chen XH, Liu YF Effect of aconitine on content of corticotropin-releasing hormone in hypothalamus of rats. Chin J of Integr Tradit West Med 1996; 16: 544-46.
12. Meng XL, Zeng N., Zhang Y., Lai X., Ran C., Cheng L. Studies on effect of active constituents of Herba Epimedii on hypothalamic monoamines neurotransmitter and other brain functions in aging rats. Chin J Chin Materia Medica 1996; 21: 683-87.
13. Meng XL, Li JY, Zhang Y., Shen YJ, Hu P., Xiao Q. Studies on neuroendocrino-immunological regulation of senile rats by using Epimedium Polysaccharides (EPS). Pharmacol Clin Chin Materia Medica 1998; 14: 19-21.
14. Zhang ZQ, Huang SJ, Yuan L. et al. Effects of Morinda officinalis oligosaccharides on performance of the swimming tests in mice and rats and the learned helplessness paradigm in rats. Chin J Pharmacol Toxicol 2001; 15: 262-65.
15. Cai B., Cui CB, Chen YH, Luo Z., Yang M., Yao Z. Antidepressant effect of inulin-type oligosaccharides from Morinda officinalis How in mice. Chin J Pharmacol Toxicol 1996; 10: 109-12.
16. Saku M. The current clinical practice of herbal medicine in psychiatry in mainland China: A review of literature. Jpn J Psychiatry Neurol 1991; 45: 825-32.
17. Wang B. Traditional Chinese medical treatment to invigorate blood and relieve stasis treatment of schizophrenia: Comparison with antipsychotics treatment. Psychiatry Clin Neurosci 1998; 52: S329-S330.
18. Andreasen NC, Grove WN Evaluation of positive and negative symptoms in schizophrenia. Psychiatry Psychobiol 1986; 1: 108-21.
19. Lindenmayer JP, Khan A., Iskander A., Abad MT, Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry 2007; 68: 368-79.
20. Chouinard G., Chouinard RA, Annable L., Jones BD Extrapyramidal symptom rating scale. Can J Neurol Sci 1980; 7: 3-9.
21. World Medical Association. Declaration of Helsinki. Recommmendations guiding medical doctors in biomedical involving human subjects. Ferney - Voltaire, France, WMA, 1989.
22. Xiang Y., Weng Y., Li W., Gao L., Chen G., Xie L., Chang Y., Tang WK, Ungvari GS Training patients with schizophrenia with the community re-entry module: A controlled study. Soc Psychiatry Psychiatr Epidemiol 2006; 41: 464-69.
23. Bonomi AE, Patrick DL, Bushnell DM, Martin M. Validation of the United States' version of the World Health Organization Quality of Life instrument. J Clin Epidemiol 2000; 53: 1-12.
24. Hao Y., Fang J. The introduce and usage of WHOQOL instrument in Chinese. Modern Rehabil 2000; 4: 1127-31.
25. Li L., Young D., Xiao S., Zhou X., Zhou L. Psychometric properties of the WHO Quality of Life questionnaire (WHOQOL-100) in patients with chronic diseases and their caregivers in China. Bull World Health Organ 2004; 82: 493-502.
26. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: A randomized double-blind study. Int Clin Psychopharmacol 2001; 16: 325-30.
27. Tang YL, Sevigny R., Mao PX, Jiang F., Cai Z. Help-seeking behaviors of Chinese patients with schizophrenia admitted to psychiatric hospital. Adm Policy Ment Health 2007; 34: 101-107.
28. Ritsner M., Gibel A., Perelroyzen G., Kurs R., Jabarin M., Ratner Y. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice. A naturalistic comparative study. J Clin Psychopharmacol 2004; 24: 582-91.
29. Hofer A., Kemmler G., Eder U., Edlinger M., Hummer M., Fleischhacker WW Quality of life in schizophrenia: The impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 2004; 65: 932-39.
30. Becchi A., Rucci P., Placentino A., Neri G., Girolamo G. Quality of life in patients with schizophrenia - comparison of self-report and proxy assessments. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 397-401.
31. Wehmeier PM, Kluge M., Schneider E., Schacht A., Wagner T., Schreiber W. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatr 2007; 31: 703-12.
32. Marwaha S., Johnson S. Schizophrenia and employment. A review. Soc Psychiatr Psychiatric Epidemiol 2004; 39: 337-49.
33. Rüesch P., Graf J., Meyer PC, Rössler W., Hell D. Occupation, social support and quality of life of persons with schizophrenic or affective disorders. Social Psychiatr Psychiatric Epidemiol 2004; 39: 686-94.
34. Wewiorski NJ, Fabian ES Association between demographic and diagnostic factors and employment outcomes for people with psychiatric disabilities: A synthesis of recent research. Mental Health Serv Res 2004; 6: 9-21.
35. Tausig M. Work and mental health. In Aneshensel CS, Phelan JC. eds. Handbook of the sociology of mental health. New York, Kluwer Academic/ Plenum Publishers, 1999.
36. Purdon SE, Jones BD, Stip E., Labelle A. et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol: The Canadian Collaborative Group for Research in Schizophrenia. Arch Gen Psychiatr 2000; 57: 249-58.
37. Zhang PL, Santos JM, Newcomer J., Pelfrey BA, Johnson MC, Erausquin GA Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophr Res 2004; 71: 137-44.
38. Naber D., Karow A., Lambert M. Subjective well-being under neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand 2005; 111: S29-s34.
39. Hofer A., Baumgartner S., Edlinger M. et al. Patient outcomes in schizophrenia I: Correlates with sociodemographic variables, psychopathology, and side effects. Eur Psychiatry 2005; 20: 386-94.
40. Becchi A., Rucci P., Placentino A., Neri G., Girolamo G. Quality of life in patients with schizophrenia-comparison of self-report and proxy assessments. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 397-401.